SYNTEKABIO, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,070 KRW | -1.08% |
|
-1.27% | -29.28% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Capitalization 1 | 307,326 | 241,650 | 115,982 | 216,882 |
| Enterprise Value (EV) 1 | 267,259 | 197,778 | 91,760 | 199,308 |
| P/E ratio | -46.9 x | -16.3 x | -25.7 x | -17.9 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 504 x | 763 x | 475 x | 1,757 x |
| EV / Revenue | 438 x | 625 x | 376 x | 1,615 x |
| EV / EBITDA | -44.3 x | -25.6 x | -8.89 x | -19 x |
| EV / FCF | - | -12,533,385 x | -52,902,285 x | -21,635,830 x |
| FCF Yield | - | -0% | -0% | -0% |
| Price to Book | 7.4 x | 8.75 x | 3.69 x | 6.95 x |
| Nbr of stocks (in thousands) | 13,362 | 13,500 | 13,518 | 15,230 |
| Reference price 2 | 23,000 | 17,900 | 8,580 | 14,240 |
| Announcement Date | 23/03/22 | 23/03/22 | 23/03/23 | 21/03/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net sales 1 | 609.7 | 316.7 | 244 | 123.4 |
| EBITDA 1 | -6,040 | -7,733 | -10,319 | -10,514 |
| EBIT 1 | -7,097 | -8,891 | -11,792 | -12,276 |
| Operating Margin | -1,164.08% | -2,807.83% | -4,832.99% | -9,947.91% |
| Earnings before Tax (EBT) 1 | -6,488 | -14,803 | -4,506 | -11,398 |
| Net income 1 | -6,488 | -14,803 | -4,506 | -11,398 |
| Net margin | -1,064.13% | -4,674.69% | -1,846.96% | -9,235.91% |
| EPS 2 | -490.0 | -1,099 | -333.5 | -796.1 |
| Free Cash Flow | - | -15,780 | -1,735 | -9,212 |
| FCF margin | - | -4,983.31% | -710.9% | -7,464.77% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 23/03/22 | 23/03/22 | 23/03/23 | 21/03/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | 40,067 | 43,873 | 24,222 | 17,574 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | -15,780 | -1,735 | -9,212 |
| ROE (net income / shareholders' equity) | - | -42.8% | -15.3% | -36.4% |
| ROA (Net income/ Total Assets) | - | -9.87% | -11.9% | -14.1% |
| Assets 1 | - | 150,049 | 37,778 | 80,666 |
| Book Value Per Share 2 | 3,109 | 2,046 | 2,327 | 2,050 |
| Cash Flow per Share 2 | 198.0 | 1,015 | 2,614 | 1,291 |
| Capex 1 | 789 | 7,479 | 8,389 | 9,364 |
| Capex / Sales | 129.39% | 2,361.89% | 3,438.08% | 7,587.97% |
| Announcement Date | 23/03/22 | 23/03/22 | 23/03/23 | 21/03/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -29.28% | 112M | |
| -13.55% | 25.74B |
- Stock Market
- Equities
- A226330 Stock
- Financials SyntekaBio, Inc.
